PubRank

Noel G McElvaney

Author PubWeight™ 104.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther 2011 2.75
2 Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011 2.37
3 Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014 2.14
4 Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012 1.93
5 Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004 1.88
6 Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med 2009 1.86
7 TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005 1.67
8 Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005 1.65
9 Endotoxin up-regulates interleukin-18: potential role for gram-negative colonization in sarcoidosis. Am J Respir Crit Care Med 2005 1.57
10 Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol 2004 1.53
11 Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002 1.52
12 Alpha-1 antitrypsin deficiency. Respir Med 2010 1.51
13 Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell 2011 1.48
14 miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and α1-antitrypsin deficiency. Am J Respir Crit Care Med 2014 1.46
15 α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses. Am J Respir Crit Care Med 2014 1.45
16 miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med 2014 1.45
17 Adult-onset nemaline myopathy presenting as respiratory failure. Respir Care 2008 1.40
18 Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003 1.38
19 α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010 1.38
20 miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol 2010 1.38
21 Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res 2007 1.31
22 Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004 1.25
23 MicroRNAs in inflammatory lung disease--master regulators or target practice? Respir Res 2010 1.24
24 Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003 1.24
25 LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 2009 1.22
26 Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem 2008 1.20
27 Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 2013 1.20
28 Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004 1.20
29 Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol 2009 1.18
30 Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res 2006 1.18
31 Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 2005 1.18
32 Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol 2007 1.17
33 Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis. Chest 2010 1.09
34 Toll-like receptor expression and function in airway epithelial cells. Arch Immunol Ther Exp (Warsz) 2005 1.09
35 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med 2010 1.08
36 Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 2009 1.07
37 Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood 2002 1.06
38 Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J Immunol 2010 1.05
39 Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008 1.03
40 Selenoprotein S/SEPS1 modifies endoplasmic reticulum stress in Z variant alpha1-antitrypsin deficiency. J Biol Chem 2009 1.01
41 Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets 2008 1.00
42 Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 2006 1.00
43 The CF-ABLE score: a novel clinical prediction rule for prognosis in patients with cystic fibrosis. Chest 2013 0.99
44 Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. J Biol Chem 2010 0.98
45 The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med 2014 0.97
46 Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology 2007 0.95
47 Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia? Respirology 2009 0.94
48 The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res 2011 0.93
49 Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. ScientificWorldJournal 2012 0.92
50 Isolation and identification of cell-specific microRNAs targeting a messenger RNA using a biotinylated anti-sense oligonucleotide capture affinity technique. Nucleic Acids Res 2013 0.92
51 The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp (Warsz) 2011 0.92
52 Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int 2013 0.91
53 Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res 2013 0.91
54 IL-8 dictates glycosaminoglycan binding and stability of IL-18 in cystic fibrosis. J Immunol 2009 0.91
55 Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp (Warsz) 2012 0.91
56 SLPI and inflammatory lung disease in females. Biochem Soc Trans 2011 0.91
57 Regulation of cystic fibrosis transmembrane conductance regulator by microRNA-145, -223, and -494 is altered in ΔF508 cystic fibrosis airway epithelium. J Immunol 2013 0.90
58 The effect of Aspergillus fumigatus infection on vitamin D receptor expression in cystic fibrosis. Am J Respir Crit Care Med 2012 0.89
59 Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J Immunol 2011 0.89
60 Inhibition of Toll-like receptor 2-mediated interleukin-8 production in Cystic Fibrosis airway epithelial cells via the alpha7-nicotinic acetylcholine receptor. Mediators Inflamm 2010 0.88
61 Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases. Biol Chem 2010 0.88
62 The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res 2014 0.88
63 Secretory leucocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J Biol Chem 2007 0.86
64 Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases. Expert Rev Anti Infect Ther 2012 0.86
65 Circulating polymers in α1-antitrypsin deficiency. Eur Respir J 2014 0.85
66 Toll-like receptors as therapeutic targets in cystic fibrosis. Expert Opin Ther Targets 2008 0.85
67 Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul 2009 0.85
68 Protein misfolding and obstructive lung disease. Proc Am Thorac Soc 2010 0.84
69 Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther 2010 0.83
70 The involvement of glycosaminoglycans in airway disease associated with cystic fibrosis. ScientificWorldJournal 2011 0.83
71 The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency. Expert Rev Respir Med 2011 0.82
72 Increased outer arm and core fucose residues on the N-glycans of mutated alpha-1 antitrypsin protein from alpha-1 antitrypsin deficient individuals. J Proteome Res 2013 0.82
73 Quantification and evaluation of the role of antielastin autoantibodies in the emphysematous lung. Pulm Med 2011 0.82
74 Increased expression of interleukin-9, interleukin-9 receptor, and the calcium-activated chloride channel hCLCA1 in the upper airways of patients with cystic fibrosis. Laryngoscope 2003 0.82
75 Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. Biologics 2009 0.82
76 Neutrophil elastase up-regulates human beta-defensin-2 expression in human bronchial epithelial cells. FEBS Lett 2003 0.81
77 Immunoevasive Aspergillus virulence factors. Mycopathologia 2014 0.81
78 In vitro activities of synthetic host defense propeptides processed by neutrophil elastase against cystic fibrosis pathogens. Antimicrob Agents Chemother 2011 0.81
79 A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2011 0.81
80 Effect of pro-inflammatory stimuli on mucin expression and inhibition by secretory leucoprotease inhibitor. Cell Microbiol 2006 0.80
81 Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. J Immunol 2014 0.80
82 Ivacaftor: from bench to bedside... and back again. Am J Respir Crit Care Med 2014 0.80
83 Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis. Expert Rev Respir Med 2012 0.80
84 Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease. Biomed Res Int 2013 0.79
85 miR-CATCH: microRNA capture affinity technology. Methods Mol Biol 2015 0.79
86 Therapeutic aerosol bioengineering of siRNA for the treatment of inflammatory lung disease by TNFα gene silencing in macrophages. Mol Pharm 2014 0.79
87 Candida species in cystic fibrosis: A road less travelled. Med Mycol 2010 0.79
88 Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory responses in bronchial epithelial cells. J Immunol 2005 0.79
89 Predictive validity of measurements of clinical competence using the team objective structured bedside assessment (TOSBA): assessing the clinical competence of final year medical students. Med Teach 2009 0.78
90 The role of TIM-containing molecules in airway disease and their potential as therapeutic targets. J Inflamm Res 2012 0.78
91 Measurement of the unfolded protein response (UPR) in monocytes. Methods Enzymol 2011 0.77
92 Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow - up in ANCA - associated vasculitis. BMC Immunol 2014 0.77
93 Endothelial progenitor cells in mothers of low-birthweight infants: a link between defective placental vascularization and increased cardiovascular risk? J Clin Endocrinol Metab 2012 0.77
94 A dry powder formulation of liposome-encapsulated recombinant secretory leukocyte protease inhibitor (rSLPI) for inhalation: preparation and characterisation. AAPS PharmSciTech 2010 0.76
95 The facilitating effect of hypertonic saline on resolution of airway inflammation in cystic fibrosis. Am J Respir Crit Care Med 2012 0.76
96 Dispelling myths regarding the safety of 'bronchoscopy in octogenerians'. Age Ageing 2009 0.75
97 Is there a therapeutic role for selenium in alpha-1 antitrypsin deficiency? Nutrients 2013 0.75
98 Reply: interactions and clarifying group-specific estimates by using stratification. Am J Respir Crit Care Med 2014 0.75
99 The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease. COPD 2015 0.75
100 Alpha-1 antitrypsin deficiency and computed tomography findings. J Comput Assist Tomogr 2005 0.75
101 Unusual Acute Sequelae of α1-Antitrypsin Deficiency: A Myriad of Symptoms With One Common Cure. Chest 2015 0.75
102 The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model. Pharm Res 2011 0.75